US biotech Gilead Sciences (Nasdaq: GILD) announced its results for the second quarter of 2020 late Thursday, sending shares in the company plummeting.
The drugmaker reported a loss of $3.33 billion, or $2.66 a share, in the period, compared with a proft of $1.88 billion, or $1.47 a share, in the year-ago quarter.
Gilead attributed the quarter’s loss to a $4.5 billion charge for the acquisition of immuno-oncology company Forty Seven in April, but, after adjusting for that charge and other factors, the firm reported earnings of $1.11 a share, which failed to hit analysts’ average estimates. Revenue fell to $5.14 billion in the quarter, down 10% from $5.68 billion in the like quarter a year ago.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze